Genomed (WAR:GEN) Other Current Liabilities: zł1.35 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:GEN Genomed SA WAR:GEN
75 GF Score
Price zł27.20
GF Value zł38.05
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Genomed Other Current Liabilities?

Genomed WAR:GEN -9.93% 75 Other Current Liabilities is zł1.35 Mil as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 75/100 and a GF Value™ of zł38.05 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Genomed's other current liabilities for the quarter that ended in Mar. 2026 was zł1.35 Mil.

Genomed's quarterly other current liabilities declined from Sep. 2025 (zł1.24 Mil) to Dec. 2025 (zł0.48 Mil) but then increased from Dec. 2025 (zł0.48 Mil) to Mar. 2026 (zł1.35 Mil).

Genomed's annual other current liabilities increased from Dec. 2023 (zł0.41 Mil) to Dec. 2024 (zł0.41 Mil) and increased from Dec. 2024 (zł0.41 Mil) to Dec. 2025 (zł0.48 Mil).

Genomed Other Current Liabilities Related Terms

Genomed Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Genomed's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomed Other Current Liabilities Chart

Genomed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.38 0.41 0.41 0.48

Genomed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.13 1.24 0.48 1.35
WAR:GEN
75GF Score
Genomed SA WAR:GEN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomed Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of zł1.35 Mil mean?
Genomed (WAR:GEN) has a Other Current Liabilities of zł1.35 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genomed.
Is Genomed's Other Current Liabilities too high?
Genomed's current Other Current Liabilities is zł1.35 Mil. Overall, Genomed has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Other Current Liabilities compare to TMO and DHR?
Genomed's Other Current Liabilities of zł1.35 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Diagnostics & Research company?
A good Other Current Liabilities depends on the Medical Diagnostics & Research industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genomed. Genomed's current Other Current Liabilities is zł1.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł38.05, compared to a current price of zł27.20 — trading 28.5% below its estimated fair value. The current Other Current Liabilities is zł1.35 Mil. Genomed's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Other Current Liabilities is zł1.35 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomed (WAR:GEN) Overvalued in 2026?

Based on GuruFocus' analysis, Genomed stock appears to be undervalued. The current stock price of zł27.20 is trading 28.5% below its estimated GF Value™ of zł38.05. GuruFocus considers Genomed to be Modestly Undervalued.

Key valuation signals for WAR:GEN:

  • Other Current Liabilities: zł1.35 Mil
  • GF Value™: zł38.05 vs. price of zł27.20 (28.5% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomed Business Description

Address Ulica Ponczowa 12, Warszawa, POL, 02-971
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
75GF Score

Get the complete analysis for WAR:GEN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł27.20
Price
zł38.05
GF Value